Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced preliminary results of matters voted upon during the Company’s 2018 annual general meeting of shareholders (the “AGM”).
August 17, 2018
· 5 min read